Efficacy of Lanreotide (LAN), Both Alone and in Combination with Targeted Therapies in a Preclinical Model of Pancreatic Neuroendocrine Tumors (pNETs)

#1734

Introduction: CLARINET trial has proven the antiproliferative effects of LAN in patients with non-functioning gastro-entero-pNETs. However, the combination of LAN with targeted therapies is widely used in clinical practice and should be further evaluated.

Aim(s): This study evaluated the effects of LAN treatment, both alone and in combination with targeted therapies (sunitinib and everolimus), in a transgenic mouse model of pancreatic NETs (pNETs).

Materials and methods: 12-week old RIP-Tag2 mice were treated with LAN (BIM-23014 at 10 µg/kg/h minipump infusion) in combination with sunitinib (40 mg/Kg/day) or everolimus (10 mg/Kg/day) by oral gavage, in randomized groups of mice. Combination treatments started two weeks after LAN monotherapy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Casanovas O

Authors: Martínez-López A, Pinto J, Teulé A, Salazar R, Culler M,

Keywords: Lanreotide, pNET,